Related by context. All words. (Click for frequent words.) 76 5 fluorouracil leucovorin 76 VEGFR2 inhibitor 76 Crofelemer budesonide foam 76 pan histone deacetylase 76 XL# anticancer compounds 76 pralatrexate injection folate analogue 76 novel tubulin binding 75 erlotinib Tarceva ® 75 Pruvel TM 75 candidates Azedra TM 75 nilotinib Tasigna ® 75 recurrent metastatic ovarian cancer 75 HGS ETR1 mapatumumab 75 Completes Patient Enrollment 75 CYT# potent vascular disrupting 75 2 methoxyestradiol 75 essential thrombocythemia ET 75 5 FU leucovorin 75 evaluating intravenous picoplatin 75 progressive metastatic prostate 75 dasatinib Sprycel ® 74 evaluating T DM1 74 FOLFOX6 chemotherapy regimen 74 oral nucleoside analogue 74 irinotecan doxorubicin oxaliplatin paclitaxel 74 refractory chronic lymphocytic 74 ATRA IV 74 FUSILEV enhances 74 trastuzumab Herceptin R 74 CG# oncolytic virus 74 oral picoplatin 74 carcinoma mCRC 74 castration resistant hormone refractory 73 MKC# MT 73 Budesonide foam crofelemer 73 non porcine pancreatic 73 Initiates Enrollment 73 LymphoStat B belimumab 73 CDK cyclin dependent 73 dependent kinase inhibitor 73 Telik logo TELINTRA 73 Initiates Phase II 73 Receives Orphan Drug Designation 73 topical antifungal product 73 antiangiogenesis therapies 73 particularly SANCTURA XR 73 sapacitabine CYC# 73 novel VDA molecule 73 IMiDs ® 73 combining voreloxin 73 developing Bicifadine serotonin 73 3 registrational trial 73 AAG geldanamycin analog 73 TRIOLEX HE# APOPTONE HE# 73 R sorafenib tablets 73 BCG refractory carcinoma 73 lintuzumab SGN 73 Submits Biologics License Application 73 delivers fluocinolone acetonide FA 73 Hormone Refractory Prostate Cancer 73 novel antimitotic agent 73 Amigal TM 73 kidney urologic 73 Epothilone D 73 Hsp# Inhibitor 73 Oral Calcitonin 72 oral prodrug 72 neuropathy sparing 72 plus prednisone prednisolone 72 evaluating tivozanib 72 known dihydropyrimidine dehydrogenase 72 Meets Primary Endpoint 72 humanized therapeutic 72 metastatic colorectal 72 Combination REOLYSIN R 72 modified glutathione analog 72 clinical trials Archexin 72 EGFr expressing metastatic colorectal 72 Panzem R 72 DG# compounds targeting 72 Mg Usa 72 Phase 2b Clinical Trial 72 products MKC# PP 72 Vitrasert R 72 pharmacogenomic translational research 72 R roscovitine CDK cyclin 72 Empatic ™ 72 NU# direct 72 elderly myelodysplastic syndromes 72 Naive Patients 72 Initiate Phase III 72 PI3K/Akt pathway inhibitor 72 Initiates Clinical Trial 72 orally administered inhibitor 72 systemic anaplastic large 72 Initiates Phase III 72 Peginterferon alfa 2b 72 tumor activated prodrug 72 Begins Dosing 72 interferon beta 1a infertility 72 oncolytic virus therapies 72 Panzem R NCD 72 stage IIIb IV 72 MCSP respectively 72 Personalized Immunotherapy 72 metastatic ocular 71 R Saizen R 71 forodesine purine nucleoside phosphorylase 71 Trial Evaluating 71 active AKT inhibitor 71 ® lenalidomide 71 novel emulsion formulation 71 influenza BCX# purine nucleoside 71 Ovitrelle R Serostim 71 CYP#A# CYP#D# 71 albiglutide currently 71 sorafenib tablets 71 evaluating RH1 targeted 71 novel orally inhaled 71 Bayer HealthCare Onyx Pharmaceuticals 71 receiving chemoradiation therapy 71 R lenalidomide 71 chemosensitizer 71 6 sulfatase 71 dimebon latrepirdine 71 sarcoma melanoma 71 Merck OSI Pharmaceuticals 71 estrogen receptor beta agonist 71 virus HCV protease inhibitor 71 peptidic compound 71 TNF Tumor Necrosis Factor 71 NASH Huntington 71 unique alkylating agent 71 Staphylococcus aureus Immune Globulin 71 Refractory Hodgkin Lymphoma 71 Mg Uk 71 ® bortezomib 71 NEBIDO VANTAS SUPPRELIN LA 71 Biogen Genentech 71 Investigational Oral 71 brand ciclesonide HFA 71 Completes Enrollment 71 GVAX ® 71 imatinib Gleevec ® 71 JAK2 Inhibitor 71 palonosetron hydrochloride Injection Dacogen 71 SinuNase TM 71 PEGylated docetaxel 71 EGFr expressing mCRC 71 including eniluracil ADH 71 Patients Treated With 71 erlotinib Tarceva R 71 Pruvel ™ 71 sanofi aventis Bayer Schering 71 docetaxel Taxotere R 71 INSPIRE Trial Phase III 71 Achieves Primary Endpoint 71 advanced metastatic renal 71 potent triglyceride lowering 71 Presents Positive 71 metastatic castration resistant 71 Aflibercept 71 agonistic human 70 Pharma Merck Serono 70 PROVENGE ® 70 monoclonal antibody IgG1 Mab 70 Tezampanel 70 vascular occlusive diseases 70 Trastuzumab DM1 70 ALTROPANE R 70 dasatinib Sprycel 70 Elotuzumab 70 candidate deforolimus 70 chemotherapeutic agents carboplatin 70 TELINTRA R 70 Vidaza ® 70 Anthracycline 70 Xeloda ® 70 Study Shows Promise 70 bevacizumab Avastin R 70 plus fludarabine 70 VANTAS ® 70 cell carcinoma RCC 70 plus dacarbazine 70 treat hyperproliferative disorders 70 includes TOLAMBA TM 70 personalized cellular immunotherapy 70 oral proteasome inhibitor 70 Randomized Phase II 70 inflammatory PDE 70 MEK Inhibitor 70 radiation chemoradiation 70 AN# topical anti 70 drug pipeline TAFA# 70 PEGylated Fab fragment 70 memantine HCl 70 vapreotide acetate 70 methylnaltrexone bromide 70 R rilonacept Injection 70 Adjuvant Treatment 70 chemotherapy molecularly targeted 70 Cloretazine ® 70 Pivotal Phase 70 generation DACH Platinum 70 bevacizumab Avastin ® 70 IMiDs R 70 intravesical infusion therapy 70 metastatic androgen independent 70 vinca alkaloids 70 acetonide FA 70 cladribine Cladribine Tablets 70 Initiate Phase 70 Submits NDA 70 Wafer polifeprosan 70 Luveris R Ovidrel R 70 Oral Fingolimod 70 TNFerade ™ 70 pegylated interferon peg IFN 70 TKB# 70 Granted Orphan Drug 70 evaluating satraplatin 70 Earns Milestone Payment 70 PNP inhibitor 70 markets Testim ® 70 Novel Oral 70 Glufosfamide 70 phenylketonuria PKU developed 70 PRN FDA Approves 70 vinca alkaloid 70 Genasense ® oblimersen 70 treat refractory angina 70 CYT# vascular disrupting 70 metastatic colorectal carcinoma 70 alpha folate receptor 70 EGFr humanized monoclonal antibody 70 Potassium Chloride Sodium Ascorbate 70 oral chemotherapeutic agent 70 docetaxel Taxotere ® 70 TRANSDUR ® 70 metastatic pancreatic 70 Prolongs Survival 70 selective angiogenic kinase inhibitor 70 Vytorin combines 70 undergoing elective percutaneous 70 interferon gamma 1b 70 targeted radiotherapeutic 70 Metastatic Melanoma 70 induced macular edema 70 albiglutide 70 Immunotherapeutic 70 non nucleoside inhibitor 70 markets COLAZAL 70 Presents Preclinical Data 70 commercializing dermatological products 70 novel synthetic PEGylated 70 Sapacitabine 70 accumulate preferentially 70 D aspartate NMDA receptor 70 developing ostarine selective 70 sunitinib Sutent ® 70 candidate XP# 69 Files IND 69 Solazed TM 69 Aeolus Pharmaceuticals Announces 69 metaglidasen 69 LymphoStat B TM 69 oral dihydropyrimidine dehydrogenase DPD 69 induced mucositis 69 Complicated Skin 69 Frozen Shoulder syndrome Adhesive 69 myocardial infarction ventricular fibrillation 69 IMiDs ® compound 69 SPRYCEL ® 69 Presents Preclinical 69 DNA methyltransferase inhibitors 69 manufactures minimally invasive 69 Shows Statistically Significant 69 Talabostat 69 including cyclosporine methotrexate 69 IMPDH inhibitor 69 aldehyde dehydrogenase ALDH2 deficiency 69 investigational oral inhibitor 69 cisplatin gemcitabine 69 fungal infections malaria tuberculosis 69 Unanimously Recommends Approval 69 metastatic castrate resistant 69 CTAP# Capsules 69 Fludara ® 69 selective A2A adenosine receptor 69 pentadentate logo R 69 vaccine GMK 69 dihydrochloride Tablets 69 cetuximab Erbitux R 69 triggers apoptosis programmed 69 occlusion PAO 69 castrate resistant prostate cancer 69 gastrointestinal stromal 69 recombinant PSMA vaccine 69 rash pruritus nausea 69 develop HBV reactivation 69 COPEGUS R 69 accessories autologous 69 Improved Progression 69 vitreoretinal disorders 69 Synta Announces 69 Selzentry Celsentri 69 approved incretin mimetic 69 Study Evaluating 69 Albuferon TM 69 By JENNIFER LEARN 69 EOquin TM phase 69 FDA Approves Novel 69 evaluating adecatumumab 69 resistant hormone refractory 69 developing ACAPODENE 69 product platforms AZX# 69 sorafenib Nexavar ® 69 oral anti arrhythmic 69 CD# CEA 69 NicVAX TM 69 investigating pralatrexate 69 TRIOLEX ™ 69 TRAIL receptor antibodies 69 Genentech Wyeth Pharmaceuticals 69 Clolar ® 69 de novo kidney transplant 69 catheter occlusion 69 molecular imaging radiopharmaceutical 69 sulfonylhydrazine class 69 irinotecan containing 69 developing adecatumumab 69 Second Pivotal Phase 69 lead molecular radiotherapeutic 69 drugs FUSILEV 69 refractory NSCLC 69 Fludarabine 69 Drug Candidate 69 topical gel formulation 69 Provectus Pharmaceuticals specializes 69 advanced carcinoid 69 Phase 2b Trial 69 cytidine nucleoside analog 69 telomerase therapeutic 69 coronary stent merged 69 generation purine nucleoside 69 Rigel R# 69 Ceflatonin R 69 EGFR expressing metastatic colorectal 69 platform HDL Mimetic 69 Initiates Phase 69 basal cell carcinoma squamous 69 Previously Untreated 69 Advanced Melanoma 69 OMP #R# 69 Receives Fast Track 69 alkylating agent 69 Cutaneous T 69 chemotherapy FOLFOX 69 Namenda Memantine HCl 69 endoscopic autofluorescence imaging 69 Xcytrin R 69 investigational monoclonal antibody 69 R metformin Concor 69 Acute Exacerbations 69 AKT inhibitor 69 bucindolol hydrochloride 69 naloxol derivative 69 Factor Receptor 69 Atripla combines 69 commercializing oxidized glutathione 69 Serostim ® 69 markets HP Acthar 69 Demonstrates Positive 69 R memantine HCl 69 Phase IIb Clinical Trial 69 R ferumoxytol Injection 69 cancer neuroendocrine tumor 69 tumor angiogenesis inhibitors 69 alfa 2a 69 R Bortezomib 69 HRPC ovarian cancer 69 developing Zerenex TM 69 Phase Ib clinical trials 69 liver colon rectal 69 metabolic disorders Saizen R 69 panitumumab Vectibix R 68 CINQUIL 68 PDX pralatrexate 68 Fovea Pharmaceuticals subsidiary 68 subtype selective NMDA receptor 68 colorectal bladder 68 Combivir Kivexa 68 alvespimycin 68 overactive bladder VANTAS R 68 ovarian esophageal 68 Kinase Inhibitor 68 HCV NS5B polymerase 68 MKC# 68 investigational pharmacologically unique 68 signal transduction inhibitor 68 IgG1 monoclonal antibody 68 familial amyloidotic polyneuropathy FAP 68 phosphorylase PNP inhibitor 68 TO AVOID PREGNANCY WHILE 68 Panzem NCD 68 acyclovir Lauriad R 68 following fluoropyrimidine oxaliplatin 68 metastatic GIST 68 next generation URAT1 68 Phase #b/#a clinical 68 orally inhaled migraine 68 PMX # heptagonist 68 indolent follicular non 68 anthracycline taxane 68 FOLOTYN ® 68 adhesion molecule EpCAM expressing 68 TURNING INSIGHTS INTO HOPE 68 XP# XP# 68 nucleoside analog 68 Dementia Related Psychosis 68 Nicotine Conjugate Vaccine 68 Vascular Disrupting Agent 68 non constipating irritable 68 metastatic hormone refractory 68 Quinamed R 68 Shows Promise Against 68 Relapsed Refractory 68 R bisoprolol Euthyrox 68 CCR9 antagonist 68 hypoxia selective 68 thrombin component 68 CYP#A# isoenzyme 68 Initiate Clinical Trial 68 compound INCB# 68 Interferon alfa 2b 68 tyrosine kinase inhibitor TKI 68 5 Fluorouracil 68 Advanced Renal Cell 68 5 HT3 antagonist 68 Demonstrates Significant 68 hypertrichosis occurred 68 hematological cancers notably 68 Inc. www.micromet inc.com 68 oral calcitonin licensed 68 synthetic lipoglycopeptide antibiotic 68 development peramivir neuraminidase 68 CysDisplay R 68 TOCOSOL Camptothecin 68 Patient Enrollment 68 ALN PCS 68 signal detection CTSD 68 RAS MAPK pathway 68 Phase 2a Clinical Trial 68 Vicriviroc 68 damage cirrhosis liver 68 NOTE POSIDUR ™ 68 small molecule glucokinase 68 cancer indications bafetinib 68 ADVANCE ILLUMINATE 68 label Lipofen R 68 Vaccine Adjuvant 68 MSCRAMM ® 68 HCl PEPCID ® famotidine 68 PEGylated anti 68 HCV RNA polymerase 68 metformin sulfonylureas 68 orally administered synthetic retinoid 68 generation radiolabeled antibody 68 TRACON Pharmaceuticals 68 Previously Treated 68 Randomized Phase 68 systemic lupus erythematosus rheumatoid 68 Romidepsin 68 Phase IIb Trial 68 Treatment Naïve 68 Camptosar ® 68 sorafenib Nexavar R 68 leading oral taxane 68 Kit CD# positive 68 Syncria albiglutide 68 Dyax logo 68 Suppository Hydrocortisone Acetate Rectal 68 Exherin 68 Chronic Hepatitis C 68 Cannabinor 68 Onyx Pharmaceuticals Announces 68 data management Clintrial 68 taxane chemotherapy administered 68 XL# XL# XL# XL# 68 folate analogue metabolic 68 unresectable locally advanced 68 CD4 monoclonal antibody 68 vinorelbine tartrate 68 GW# [003] 68 Gel repository corticotropin injection 68 anti VEGF aptamer 68 unresectable Stage III 68 psoriasis inflammatory bowel 68 daily injectable lipoglycopeptide 68 EMD # 68 Motesanib 68 tumors GIST 68 Phase 2a Trial 68 RANK Ligand inhibitor 68 Shigatoxin producing E. coli 68 Brentuximab Vedotin SGN 68 oropharyngeal candidiasis OPC 68 pipeline GlycoPEG GCSF 68 inhibitor PPI 68 Peginterferon 68 Enrolls First 68 nano particle tumor suppressor 68 adjuvant GIST 68 prokinetic agent 68 bone marrow reticulin deposition 68 IMiDs 68 ENL recurrence 68 nephropathic cystinosis cystinosis 68 ocular formulation 68 FOLFOX6 68 IL# PE#QQR 68 Mylan Receives Approval 68 Announces Poster Presentations 68 Voreloxin 68 investigational immunotherapy 68 refractory cutaneous T 68 RON Notch 68 EGFR TKI 68 anti miRs antisense oligonucleotide 68 anionic backbone 68 EGFR expressing mCRC 68 Through Glycoscience R 68 telomerase inhibitor drug 68 Aloprim TM allopurinol sodium 68 NATIONAL ECONOMIC COUNCIL DIRECTOR 68 pipeline ImmunoGen collaborators 68 somatropin Kuvan R 68 treat chronic sinusitis 68 CYP#A# substrate 68 Hematology Molecular Pathology 68 hormone refractory metastatic prostate 68 Improves Survival 68 Pegloticase 68 relapsed leukemia 68 Receives Approvable Letter 68 Tramiprosate ALZHEMED TM 68 USP Tablets VISICOL ® 68 Pruvel ™ prulifloxacin 68 YOUR LOCAL ANIMAL SHELTER 68 PEGINTRON REBETOL combination 68 cyclophosphamide doxorubicin vincristine 68 anti PlGF 68 Soft Tissue Sarcoma 68 alfimeprase direct 68 IAP inhibitor 68 aflibercept VEGF Trap 68 DepoCyt ® Abelcet ® 68 Intravitreal 68 HARD ENOUGH WITH 68 forodesine 68 Antibody Drug Conjugate 68 infliximab monotherapy 68 investigational antiplatelet agent 68 ATC ovarian cancer 68 Announces Tentative Approval 68 Oral Solution OSMOPREP 68 Hedgehog Pathway Inhibitor 68 anthracycline containing 68 Dupuytren Disease 68 cosmetic cosmeceutical products 68 Obatoclax 67 Tibotec Therapeutics division 67 R bortezomib 67 sapropterin dihydrochloride 67 cyclophosphamide methotrexate 67 R MSCRAMM 67 interferon alpha IFN 67 liposomal formulation 67 targeting miR 67 % pramoxine HCl 67 Pivotal Phase III 67 novel therapeutic antibodies 67 Investigational Treatment 67 Antitumor Activity 67 Perifosine KRX 67 Avise MCV SM 67 Nasdaq XTLB 67 Curis collaborator Genentech 67 METOZOLV ™ ODT metoclopramide 67 MKC# MKC# PP 67 Intravitreal injections 67 visit www.genenews.com 67 selective inverse agonist 67 Colaris Colaris AP 67 severe oral mucositis 67 GATTEX TM 67 Phase III Trial 67 dyslipidemia hypertension diabetes 67 J Antimicrob Chemother 67 used DNA alkylating 67 Chemotherapeutic 67 Ribavirin causes 67 unproven detoxification 67 website www.cellgenesys.com 67 immunotherapeutic agent 67 gastrointestinal mucositis 67 receptor tyrosine kinase inhibitor 67 Anti Tumor 67 Reports Preclinical Data 67 5 FU capecitabine 67 FEMALES SHOULD BE ADVISED 67 itraconazole Sporanox 67 ThermoDox R 67 testing huN# DM1 67 hormone LHRH antagonist 67 Annamycin 67 infectious diseases autoimmune diseases 67 USP Tablets PEPCID 67 delta opioid receptor 67 non peptidic protease 67 orthodontics braces oral 67 Syncria R 67 renal failure interstitial lung 67 inhibits dihydrofolate reductase 67 Capsulitis 67 certain protein tyrosine 67 Merck Serono Nycomed 67 hypoxia activated prodrug 67 * olmesartan medoxomil 67 prednisone prednisolone plus 67 Gemzar ® 67 lexidronam injection 67 PROSTASCINT R 67 BiovaxID TM 67 Anti Tumor Activity 67 deCODE ProstateCancer TM 67 BENLYSTA TM 67 targeted anticancer biopharmaceuticals 67 Desvenlafaxine Succinate 67 Successfully Completes Phase 67 estramustine 67 sirtuin inhibitor program 67 Clinical Trial Results 67 thalidomide Thalomid 67 R famotidine 67 myelodysplastic myeloproliferative diseases 67 Diomed EVLT R 67 J Am Coll 67 Pooled Analysis 67 tranquilizers diazepam 67 oral ghrelin agonist 67 atrial fibrillation budiodarone ATI 67 sulfonylurea glimepiride 67 SANCTURA XR NEBIDO 67 oral beclomethasone dipropionate 67 oral luteinizing hormone 67 Exelixis compounds 67 Amgen Neulasta R 67 Emergent marketed 67 Zorbtive TM 67 registrational Phase 67 include Healive TM 67 CAUTIONARY STATEMENT UNDER 67 advanced unresectable 67 CD#.# DOES NOT ENDORSE 67 inhibitor COX 67 Vitamin D analogue 67 OMNARIS HFA 67 var arrContent = 67 SPL# Gel vaginal microbicide 67 pegylated interferons 67 PROACT Phase 2 67 Launches Generic Version 67 DIRECT Trial 67 Europe entitled MINDSET 67 Renal Impairment 67 GRNOPC1 contains 67 Unigene nasal calcitonin 67 M# rationally 67 BENLYSTA belimumab 67 product TNFerade TM 67 biologic antibody 67 USP Tablets MOVIPREP ® 67 vaccines oncolytic virus 67 oritavancin semi 67 Treatment Naive Patients 67 ® decitabine 67 TM Aganocide 67 Group SmartBill ® 67 CEL SCI Phase III 67 Endologix Powerlink System 67 evaluating satraplatin plus 67 includes VIAtab TM 67 ARRY # 67 specific ZFP Nucleases 67 Altera Nebulizer System 67 clinical trials Archexin ® 67 Preclinical Data 67 ADP receptor antagonist 67 5 HT2A inverse 67 Therapeutic Competitors Companies 67 orderonlineviagra 67 PROCTOCORT R Suppository Hydrocortisone 67 Romiplostim 67 Tumour Vascular Disrupting Agent 67 sunitinib Sutent 67 combines Zetia 67 evaluating bafetinib 67 Bosutinib 67 RNAi Therapeutic 67 events thrombocytopenia neutropenia 67 GVAX R 67 neuromuscular spasm 67 Hereafter Inception Iron Man 67 CTA# Injection 67 Other ImmunoGen collaborative 67 First Patient Enrolled 67 aplastic anemia AA 67 milnacipran HCI 67 Initiates Clinical 67 candidate AQ4N 67 multi kinase inhibitor 67 BRIM2 67 substantially excreted 67 prednisone CHOP 67 d l leucovorin 67 SinuNase ™ 67 developing Zerenex ferric 67 inflammatory autoimmune diseases 67 cytarabine daunorubicin 67 Hematological Malignancies 67 gemcitabine Gemzar 67 Metastatic Colorectal Cancer 67 motexafin gadolinium Injection 67 cutaneous T 67 recurrent glioblastoma multiforme 67 relapsed MM 67 PDGFR B 67 Daclizumab 67 dihydroergotamine mesylate DHE 67 mitoxantrone plus 67 promotes MERREM ® 67 Zemiva TM 67 AAG KOS 67 phenyl salicylate methylene blue 67 rusalatide acetate 67 gefitinib Iressa 67 evaluating mipomersen 67 Akt pathway associated 67 pancreatic prostate 67 Cetrorelix 67 commercialize CorMedix drug 67 class mGluR5 inhibitor 67 Aurora Kinase 67 Nasdaq AEGR 67 NS5b 67 TRISCUIT crackers 67 microRNA Therapeutics 67 var arrMeta = 67 Pemetrexed 67 Methylnaltrexone 67 hyperplasia BPH 67 ISTA Pharmaceuticals Announces 67 GALNS N acetylgalactosamine 67 cause mesothelioma asbestosis 67 Vinorelbine 67 infectious diseases autoimmune 67 ® bevacizumab 67 Boehringer Ingelheim MedImmune 67 toenail onychomycosis 67 Letairis ambrisentan 67 Cytogen marketed 67 myelofibrosis polycythemia vera 67 Retisert R 67 sodium Injection 67 Teva Provides Update 67 Entereg R 67 Genentech sanofi aventis 67 Relapsed Multiple Myeloma 67 Custirsen 67 Statin medicines sold 67 community AABB SmartBrief 67 squamous non 67 HER2 Positive 67 acute peptic ulcer 67 FDA Accepts 67 mocetinostat MGCD# 67 candidate SMaRT Replacement 67 MAGE A3 ASCI 67 Array BioPharma Reports 67 5 HT2A serotonin 67 herpetic keratitis 67 2hours #mins #.#secs M 67 worsening thrombocytopenia 67 Guinness NF H 67 opioid naive 67 enhanced skin permeation 67 mertansine 67 vomiting anorexia stomatitis 67 GVAX immunotherapies 67 ALN HPN 67 refractory gout 67 successfully commercialize Iluvien 67 GVAX Immunotherapy 67 generation Hsp# inhibitor 67 STRIKE PRICE COMPARES TO 67 CRM# Protein 67 Protease Inhibitor 67 topically applied SEPA 67 Atypical Hemolytic Uremic Syndrome 67 5 lipoxygenase inhibitor 66 including thyroiditis RA 66 Am J Obstet 66 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 66 Vitrasert ® 66 mGluR5 negative 66 Monotherapy 66 ZACTIMA TM ZD# 66 agents Tabun Sarin 66 plus Copegus R 66 polyneuropathy HIV DSP 66 Submits Response 66 HIV AIDS neuropathic pain 66 related CMV Retinitis 66 mucositis ProLindac ™ 66 Cardium Therapeutics TM 66 prostate cancer HRPC 66 Plaque Psoriasis 66 CCX# B 66 NEEDS WHICH MAY CAUSE 66 candidates Azedra 66 Schering Plough Remicade 66 Seliciclib CYC# 66 THAT ARE SUBJECT TO 66 resistant systolic hypertension 66 HYVISC ® treatment 66 TNFerade TM 66 Telik Announces 66 beta 1a 66 Temodar ® 66 benzoic acid hyoscyamine sulfate 66 microsurgical disciplines 66 Renal Cell Carcinoma 66 ® DS methenamine 66 pharmacologically active isomer 66 CTAP# 66 include Altastaph TM 66 Testosterone MDTS ® 66 Stage IIIB IV 66 Omacetaxine 66 Avise PG SM 66 Patients Receiving 66 Cytarabine 66 Epivir R 66 Pharmacyclics Announces 66 gemcitabine chemotherapy 66 individualized cellular immunotherapy 66 ergot derivatives 66 Transgenomic Pharmacogenomics Services 66 ENABLE Phase 2 66 non splenectomized 66 4SC AG ISIN DE# 66 Emtriva Viread 66 solid tumors ZYBRESTAT 66 AP Photo CAR# 66 reduce serum phosphate 66 mesylate tablets approved 66 HER2 positive metastatic breast 66 unresectable recurrent 66 Improves Outcomes 66 Ostarine ™ 66 3TC lamivudine 66 product candidate Lpathomab 66 galiximab 66 OAB overactive bladder 66 developing Surfactant Replacement 66 unresectable tumors 66 selective kinase inhibitor 66 Inhalation Aerosol 66 acting fibrinolytic 66 pegylated interferon alfa 2a 66 cyclophosphamide chemotherapy 66 2 inhibitor CYT# 66 polysaccharide polymer 66 Aflibercept VEGF Trap 66 delay bone metastases 66 diets Nevius 66 decreased matrix metalloproteinase 66 paclitaxel Taxol ® 66 targets EpCAM expressing 66 molecular therapeutics immunotherapies 66 Cetrorelix pamoate 66 Dose Ranging 66 First Patient Dosed 66 Luramist TM 66 ELADUR ™ 66 lupus hepatitis C 66 Severe Sepsis 66 YONDELIS 66 humanized interleukin 6 66 Orally administered 66 oxybutynin ATD TM 66 metastatic malignant 66 TLR7 agonist 66 potent CYP#A# inhibitors 66 oral Janus kinase 66 MOVIPREP R 66 carbamazepine phenobarbital phenytoin rifampin 66 humanised monoclonal antibody 66 By QianMian #-#-# 66 BioSante Pharmaceuticals Announces 66 sorafenib Nexavar 66 Plicera TM 66 auristatin E MMAE 66 Randomized Double blind 66 prostate secretory 66 overactive bladder AA# 66 R chorionic gonadotropin 66 Drug Shows Promise 66 ® chorionic gonadotropin 66 Mali Mauritius Mozambique 66 delivery polymer matrix 66 apoptosis inducer 66 Squibb Genentech 66 arsenic trioxide injection 66 5 lipoxygenase activating 66 folinic acid FA 66 Augment TM 66 demonstrated antitumor activity 66 systemic juvenile idiopathic 66 Cloretazine 66 endocrine refractory 66 ribavirin RBV 66 evaluating ASA# 66 Newly Diagnosed Multiple Myeloma 66 Dose Ranging Study 66 AND TO REOFFER 66 plus prednisone 66 PINPOINT TM System 66 peripherally acting 66 osteolytic bone disease 66 sodium sulfate sodium chloride 66 Melphalan 66 evaluating Actimmune 66 gastro intestinal inflammation 66 lenalidomide Revlimid R 66 please visit www.abraxane.com 66 HuMax TAC 66 BY DANNY GALLAGHER 66 Nexavar ® 66 Westerplatte glory 66 sapropterin dihydrochloride Tablets 66 TM pralatrexate injection 66 Vidaza R 66 P#X# antagonist 66 XL# XL# 66 Phase III Clinical Trial 66 cisplatin carboplatin 66 ERBITUX cetuximab 66 NPC 1C 66 psoriasis rheumatoid arthritis 66 evaluating Xcytrin 66 novel topoisomerase 66 Solution XOPENEX HFA 66 vaginal candidiasis 66 class anticancer quinolone 66 Ph + acute lymphoblastic 66 Advanced CustomVue Wavefront 66 bkeva@cnc.com 66 Castration Resistant Prostate Cancer 66 THAT ARE DIFFICULT TO 66 TRANSDUR ™ 66 Malignant Glioma 66 DP VPA 66 MULLIGAN FAMILY FUN CENTER 66 neuropathic pain metabolic diseases 66 Bilive R combined 66 either acutely decompensated 66 Ixempra 66 respiratory allergy dermatological 66 Locteron combines 66 small molecule thrombopoietin 66 targeted immunotherapies 66 estrogen receptor antagonist 66 Retisert ® 66 Node Positive 66 Relapsed Refractory Multiple Myeloma 66 corticotropin injection 66 sodium glucose cotransporter 66 Planetwide Media My 66 syndrome overactive bladder 66 Delta opioid receptor 66 SIX ROG VX 66 Tyrosine Kinase Inhibitor 66 LEVADEX TM 66 developing KL4 surfactant 66 Genentech Boehringer Ingelheim 66 hygienic cleansing 66 include ColorectAlert TM